Global Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Vaccine Market Analysis  

The global vaccine market is witnessing robust growth, driven by increasing awareness of preventive healthcare and advancements in vaccine technology. Recent developments include the rapid deployment of mRNA vaccines, particularly highlighted during the COVID-19 pandemic, which have set a precedent for future vaccine development across various infectious diseases. This innovative technology accelerated vaccine development timelines and demonstrated the potential for enhanced efficacy and safety. In addition, ongoing research into combination vaccines is expanding the market by enabling immunization against multiple diseases with a single shot, thus improving patient compliance and coverage rates. Regulatory agencies have also been pivotal in facilitating faster approvals for new vaccines, allowing for timely responses to emerging health threats. Furthermore, the rising prevalence of vaccine-preventable diseases and an increasing patient population are propelling market demand. Government initiatives aimed at expanding vaccination programs, particularly in low- and middle-income countries, are also contributing to market growth. With these advancements, the vaccine market is poised for continued expansion, enhancing global health outcomes and addressing the challenges posed by infectious diseases.

Vaccine Market Size

The global vaccine market size was valued at USD 74.80 billion in 2023 and is projected to reach USD 168.69 billion by 2031, with a CAGR of  10.70% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vaccine Market Trends

“Increasing Demand for Innovative Vaccination Solutions”

El mercado mundial de vacunas está experimentando un crecimiento significativo, impulsado por la creciente demanda de soluciones de vacunación innovadoras y un mayor enfoque en la salud pública. Una tendencia notable es el cambio hacia la tecnología de vacunas de ARNm, que ganó prominencia durante la pandemia de COVID-19 con el exitoso despliegue de vacunas como Pfizer-BioNTech y Moderna. Dicha tecnología permitió un desarrollo rápido y altas tasas de eficacia y abrió nuevas vías para abordar otras enfermedades infecciosas, como la influenza y el virus del Zika , a través de plataformas similares. Además, el auge de las vacunas combinadas está mejorando la dinámica del mercado, lo que permite a los proveedores de atención médica administrar inmunizaciones para múltiples enfermedades en una sola dosis, mejorando así la adherencia del paciente. La vacuna pentavalente, que ofrece protección contra cinco enfermedades, ejemplifica esta tendencia al satisfacer la necesidad de estrategias de inmunización más amplias. A medida que la conciencia pública y el apoyo gubernamental a las iniciativas de vacunación continúan creciendo, el mercado de vacunas está bien posicionado para expandirse, lo que contribuye a mejorar los resultados de salud a nivel mundial.

Alcance del informe y segmentación del mercado de vacunas      

Definición del mercado de vacunas

Las vacunas son preparaciones biológicas diseñadas para proporcionar inmunidad contra enfermedades infecciosas específicas. Por lo general, contienen formas debilitadas o inactivadas de patógenos (como virus o bacterias) o componentes de estos patógenos, como proteínas o azúcares. Cuando se administran, las vacunas estimulan el sistema inmunológico para que reconozca y recuerde el patógeno, lo que permite que el cuerpo prepare una respuesta más rápida y eficaz si se expone a la enfermedad real en el futuro. Este proceso ayuda a prevenir enfermedades y reducir la propagación de enfermedades infecciosas dentro de las comunidades. Las vacunas pueden administrarse por diversas vías, incluidas inyecciones, formulaciones orales y aerosoles nasales, y son un componente crucial de las estrategias de salud pública en todo el mundo.

Dinámica del mercado de vacunas

Conductores

• Aumento de la incidencia de enfermedades infecciosas

La creciente incidencia mundial de enfermedades infecciosas es un factor importante que impulsa la demanda de vacunas. Los recientes brotes de enfermedades como el sarampión, la gripe y la COVID-19 han puesto de relieve el papel esencial de la vacunación para controlar la propagación de enfermedades infecciosas y reducir su impacto en la salud pública. Según datos de la Organización Mundial de la Salud (OMS) publicados en julio de 2023, la cobertura de la tercera dosis de la vacuna contra la difteria, el tétanos y la tos ferina (DTP3) aumentó del 81% en 2021 al 84% en 2022. Además, el porcentaje de niños que reciben la primera dosis de la vacuna contra el sarampión aumentó ligeramente del 81% en 2021 al 83% en 2022. Estos resultados reflejan los avances en los esfuerzos mundiales de vacunación y un énfasis creciente en los programas de inmunización en todo el mundo, lo que mejora aún más el mercado de las vacunas.

• Aumento de la financiación para la investigación de vacunas

El aumento de la financiación de las entidades gubernamentales y las organizaciones privadas para la investigación de vacunas está impulsando el desarrollo de nuevas vacunas y ampliando el mercado. El Proyecto NextGen, iniciado por el Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS), tiene como objetivo acelerar y mejorar el desarrollo rápido de vacunas y tratamientos de próxima generación a través de asociaciones público-privadas, respaldadas por una inversión inicial de 5.000 millones de dólares. Este aumento de la financiación está facilitando los esfuerzos de investigación centrados en una amplia gama de enfermedades, incluidas las enfermedades infecciosas emergentes y el cáncer. Como resultado, existe una sólida cartera de nuevas vacunas que abordan necesidades médicas no satisfechas y estimulan el crecimiento del mercado.

Oportunidades

• Ampliación de los programas de vacunación

La expansión de los programas de vacunación está transformando significativamente el mercado, especialmente en los países en desarrollo donde el acceso a las vacunas sigue siendo limitado. Según la Organización Mundial de la Salud (OMS), los datos de varios países revelan que siguen existiendo barreras e inequidades en el acceso a las vacunas pediátricas, ya que la vacuna contra el rotavirus se utiliza en solo el 58% de los países de ingresos medios que las adquieren por sí mismos. Asimismo, la vacuna contra el virus del papiloma humano se administra en solo el 41% de los países de ingresos bajos, a pesar de que estos países enfrentan una carga considerable de cáncer de cuello uterino y tienen un acceso limitado a otros servicios de atención médica preventivos y curativos. El aumento de las inversiones en infraestructura de atención médica e iniciativas de vacunación puede mejorar la cobertura de vacunación y mitigar el impacto de las enfermedades prevenibles por vacunación en estas regiones, lo que presenta una oportunidad de mercado sustancial para los fabricantes de vacunas.

• Desarrollo de vacunas de próxima generación

La aparición de vacunas de próxima generación, incluidas las vacunas de ARNm y recombinantes, ofrece importantes oportunidades de innovación y crecimiento en el mercado. Estas vacunas ofrecen ventajas como plazos de desarrollo más rápidos, mayor eficacia y mejores perfiles de seguridad. La adquisición de Affinivax, Inc. por parte de GSK plc ilustra el potencial asociado a las vacunas de próxima generación en el mercado. Los esfuerzos pioneros de Affinivax en la creación de vacunas neumocócicas de próxima generación, como la AFX3772, ponen de relieve la capacidad de estas vacunas para ofrecer mejoras sustanciales con respecto a las tecnologías de vacunas tradicionales. Empresas como GSK están invirtiendo en el desarrollo de vacunas de próxima generación para abordar las necesidades cambiantes de los sistemas sanitarios de todo el mundo, creando así nuevas oportunidades de crecimiento e innovación en el sector de las vacunas.

Restricciones/Desafíos

• Reacciones adversas y efectos secundarios involucrados

High development costs represent a significant challenge in the vaccines market, as the research and development (R&D) phase is often both expensive and time-consuming. For instance, developing a new vaccine can require billions of dollars and several years of research, which includes preclinical studies, clinical trials, and regulatory approvals. The development of the COVID-19 vaccines, where companies like Moderna and Pfizer invested heavily in R&D, often supported by government funding and partnerships. However, pharmaceutical companies targeting less profitable markets, such as vaccines for neglected tropical diseases, face additional financial risks. These markets often lack sufficient return on investment, leading to fewer companies willing to invest in the necessary research. Consequently, this financial burden can deter innovation and limit the availability of vaccines for diseases that predominantly affect low-income populations, thereby impacting global vaccines market.

• Cold Chain Requirements

Cold chain requirements present a significant market challenge in the vaccine distribution process, as many vaccines need to be stored and transported at specific temperature ranges to maintain their efficacy and safety, directly impacting market accessibility and effectiveness. For instance, vaccines like the Pfizer-BioNTech COVID-19 vaccine initially required ultra-low temperature storage at around -70 degrees Celsius (-94 degrees Fahrenheit), complicating logistics and limiting accessibility, particularly in low-resource settings where such infrastructure is often lacking. Such challenge is further exacerbated by the fact that even with more stable vaccines, maintaining the cold chain can be difficult due to power outages, inadequate refrigeration facilities, and transportation issues in remote areas. Consequently, these logistical hurdles can lead to vaccine spoilage, reduced supply, and increased costs, ultimately hampering vaccination efforts and limiting market growth potential.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Vaccine Market Scope

The market is segmented on the composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Composition

• Combination Vaccines
• Monovaccines

Type

• Subunit Vaccines
• Recombinant Vaccines
• Polysaccharide Vaccines
• Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• DNA Vaccines

Kind

• Routine Vaccine
• Recommended Vaccine
• Required Vaccine

Age of Administration

• Pediatric Vaccine
• Adult Vaccine

Diseases

• Pneumococcal Disease
• Measles
• Mumps and Varicella
• DPT (Diphtheria, Pertussis, and Tetanus)
• Hepatitis
• Influenza
• Typhoid
• Meningococcal
• Rabies
• Japanese Encephalitis
• Yellow Fever
• Others

Route of Administration

• Injectable
• Oral
• Nasal

End User

• Community Hospitals
• Hospitals
• Specialty Centres
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Vaccine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the market, driven by its strong healthcare infrastructure and the presence of prominent industry players. The introduction of innovative vaccines, including those for rotavirus, pneumococcal conjugate, and human papillomavirus, presents significant opportunities for cost reduction and the establishment of new supply chains and distribution networks. Moreover, the region's investment in research and development, coupled with favorable government policies, further enhances the potential for growth in vaccine production and accessibility, ultimately benefiting public health initiatives across the continent.

Asia-Pacific region is projected to experience substantial growth in the coming years, driven by an expanding patient population that necessitates enhanced healthcare services. In addition, increased investments in healthcare infrastructure and technology are set to bolster service delivery and access to medical treatments. Furthermore, strong government support and initiatives aimed at improving public health systems are likely to contribute to the overall development and expansion of the healthcare market in this dynamic region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Vaccine Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Vaccine Market Leaders Operating in the Market Are:

• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Sanofi (France)
• Serum Institute of India Pvt. Ltd. (India)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Indian Immunologicals Ltd. (India)
• Axplora (France)
• Merck KGaA (Germany)
• Charles River Laboratories (U.K.)
• uniQure N.V. (Netherlands)
• Waisman Biomanufacturing (U.S.)
• Creative Biogene (U.S.)
• Aldevron LLC (U.S.)
• Addgene (U.S.)
• Oxford Biomedica PLC (U.K.)
• Thermo Fisher Scientific Inc. (U.S.)
• FUJIFILM Corporation (Japan)
• Spark Therapeutics, Inc. (U.S.)

Latest Developments in Vaccine Market

• In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and collaborate on the development of innovative combination vaccines targeting both COVID-19 and influenza. This strategic alliance enables both companies to utilize their respective expertise and resources to deliver advanced vaccine solutions to the market
• In March 2023, CSL Limited opened a new vaccine research and development facility in Waltham, Massachusetts, aimed at creating advanced vaccines utilizing disruptive technologies, including next-generation mRN

SKU-53099